TP53 and cancer: We found that overlaps between CH mutations and actionable somatic mutations occurred much more frequently in the genes TP53 (30 of 92 cancer patients, 32.6%; Fisher's exact test; FDR = 1.68 × 10−22) and KRAS (15 of 92 cancer patients, 16.3%; Fisher's exact test; FDR = 7.25 × 10−19).